RS61267B1 - Supstituisani hromani i postupci za upotrebu - Google Patents

Supstituisani hromani i postupci za upotrebu

Info

Publication number: RS61267B1
Authority: RS; Serbia
Prior art keywords: substituted chromanes; chromanes; substituted
Prior art date: 2014-10-31

Application number

RS20201328A

Other languages

English (en)

Inventor

Philip R Kym

Xueqing Wang

Xenia B Searle

Bo Liu

Ming C Yeung

Robert J Altenbach

Eric Voight

Andrew Bogdan

John R Koenig

Stephen N Greszler

Original Assignee

Abbvie Overseas Sarl

Galapagos Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-31

Filing date

2015-10-28

Publication date

2021-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55858309&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS61267(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-28 Application filed by Abbvie Overseas Sarl, Galapagos Nv filed Critical Abbvie Overseas Sarl

2021-01-29 Publication of RS61267B1 publication Critical patent/RS61267B1/sr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

RS20201328A 2014-10-31 2015-10-28 Supstituisani hromani i postupci za upotrebu RS61267B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462073573P	2014-10-31	2014-10-31
PCT/US2015/057837 WO2016069757A1 (en)	2014-10-31	2015-10-28	Substituted chromanes and method of use
EP15854320.7A EP3212189B1 (en)	2014-10-31	2015-10-28	Substituted chromanes and method of use

Publications (1)

Publication Number	Publication Date
RS61267B1 true RS61267B1 (sr)	2021-01-29

Family

ID=55858309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20201328A RS61267B1 (sr)	2014-10-31	2015-10-28	Supstituisani hromani i postupci za upotrebu

Country Status (35)

Country	Link
US (3)	US9642831B2 (sr)
EP (1)	EP3212189B1 (sr)
JP (1)	JP6676646B2 (sr)
KR (3)	KR20230040378A (sr)
CN (1)	CN107405337B (sr)
AR (1)	AR102492A1 (sr)
AU (1)	AU2015339336B2 (sr)
CA (2)	CA3191010A1 (sr)
CL (1)	CL2017001061A1 (sr)
CO (1)	CO2017005421A2 (sr)
CR (1)	CR20170227A (sr)
CY (1)	CY1123524T1 (sr)
DK (1)	DK3212189T3 (sr)
DO (1)	DOP2017000104A (sr)
EC (1)	ECSP17033565A (sr)
ES (1)	ES2830279T3 (sr)
HR (1)	HRP20201666T1 (sr)
HU (1)	HUE052373T2 (sr)
IL (1)	IL251996B (sr)
LT (1)	LT3212189T (sr)
MX (2)	MX366556B (sr)
MY (1)	MY194313A (sr)
PE (1)	PE20171106A1 (sr)
PH (1)	PH12017500797A1 (sr)
PL (1)	PL3212189T3 (sr)
PT (1)	PT3212189T (sr)
RS (1)	RS61267B1 (sr)
RU (1)	RU2718060C2 (sr)
SG (2)	SG11201703391VA (sr)
SI (1)	SI3212189T1 (sr)
TW (1)	TWI691496B (sr)
UA (1)	UA122965C2 (sr)
UY (1)	UY36379A (sr)
WO (1)	WO2016069757A1 (sr)
ZA (1)	ZA201703075B (sr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5409010B2 (ja)	2005-12-28	2014-02-05	バーテックスファーマシューティカルズインコーポレイテッド	Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR20130056244A (ko)	2010-04-22	2013-05-29	버텍스 파마슈티칼스 인코포레이티드	시클로알킬카르복스아미도-인돌 화합물의 제조 방법
PL3925607T3 (pl)	2014-04-15	2023-10-30	Vertex Pharmaceuticals Incorporated	Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
US9840513B2 (en)	2015-07-16	2017-12-12	Abbvie S.Á.R.L.	Substituted tricyclics and method of use
AU2016333907A1 (en)	2015-10-09	2018-04-12	AbbVie S.à.r.l.	Novel compounds for treatment of cystic fibrosis
JP2018530557A (ja)	2015-10-09	2018-10-18	アッヴィ・エス・ア・エール・エル	置換ピラゾロ［３，４−ｂ］ピリジン−６−カルボン酸およびこの使用
CA3001096A1 (en)	2015-10-09	2017-04-13	Abbvie S.A.R.L.	N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
AU2017256172A1 (en) *	2016-04-26	2018-09-06	AbbVie S.à.r.l.	Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en)	2016-06-03	2018-11-27	Abbvie S.Á.R.L.	Heteroaryl substituted pyridines and methods of use
US10399940B2 (en)	2016-10-07	2019-09-03	Abbvie S.Á.R.L.	Substituted pyrrolidines and methods of use
US9981910B2 (en)	2016-10-07	2018-05-29	Abbvie S.Á.R.L.	Substituted pyrrolidines and methods of use
EP3558982A1 (en)	2016-12-20	2019-10-30	AbbVie S.À.R.L.	Deuterated cftr modulators and methods of use
TW201831471A (zh)	2017-02-24	2018-09-01	盧森堡商艾伯維公司	囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
CN106977483A (zh) *	2017-06-02	2017-07-25	遵义医学院	一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
WO2019003148A1 (en) *	2017-06-28	2019-01-03	Glaxosmithkline Intellectual Property Development Limited	MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE
US10988454B2 (en)	2017-09-14	2021-04-27	Abbvie Overseas S.À.R.L.	Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019070492A1 (en) *	2017-10-02	2019-04-11	Merck Sharp & Dohme Corp.	CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
WO2019193062A1 (en)	2018-04-03	2019-10-10	Abbvie S.Á.R.L	Substituted pyrrolidines and their use
US11345691B2 (en)	2019-06-03	2022-05-31	AbbVie Global Enterprises Ltd.	Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TW202115014A (zh)	2019-07-12	2021-04-16	美商奧佛麥德公司	用於治療囊腫纖維化之化合物
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022150174A1 (en)	2021-01-06	2022-07-14	AbbVie Global Enterprises Ltd.	Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220213041A1 (en)	2021-01-06	2022-07-07	AbbVie Global Enterprises Ltd.	Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
CN113234113B (zh) *	2021-05-31	2023-09-01	江西师范大学	一种构建1,2-顺式-2-硝基-葡萄糖苷和半乳糖糖苷的方法
CN113372318A (zh) *	2021-07-02	2021-09-10	贵州中医药大学	7-甲氧基-4’-甲酸甲酯二氢黄酮的制备方法及装置
WO2023150237A1 (en)	2022-02-03	2023-08-10	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2023150236A1 (en)	2022-02-03	2023-08-10	Vertex Pharmaceuticals Incorporated	Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
WO2023154291A1 (en)	2022-02-08	2023-08-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2024056798A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators
WO2024056791A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
US20240164146A1 (en)	2022-11-11	2024-05-16	Samsung Display Co., Ltd.	Display device and electronic device having the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6221335B1 (en) *	1994-03-25	2001-04-24	Isotechnika, Inc.	Method of using deuterated calcium channel blockers
CN1938279B (zh)	2004-01-30	2011-09-14	沃泰克斯药物股份有限公司	Atp-结合***转运蛋白调控剂
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
WO2007021982A2 (en)	2005-08-11	2007-02-22	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
SI1945632T1 (sl)	2005-11-08	2014-03-31	Vertex Pharmaceuticals Incorporated	Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
US20120232059A1 (en)	2005-11-08	2012-09-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette Transporters
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
CN103214450B (zh) *	2005-12-28	2016-10-05	弗特克斯药品有限公司	作为atp-结合盒转运蛋白调节剂的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
HUE036165T2 (hu) *	2006-04-07	2018-06-28	Vertex Pharma	ATP-kötõ kazetta transzportereinek modulátorai
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
NZ576642A (en)	2006-11-03	2011-11-25	Vertex Pharma	Azaindole derivatives as cftr modulators
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
JP5497633B2 (ja)	2007-05-09	2014-05-21	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒのモジュレーター
EP2217572B1 (en)	2007-11-16	2013-11-06	Vertex Pharmaceuticals Incorporated	Isoquinoline modulators of atp-binding cassette transporters
EP2237768A2 (en) *	2007-12-07	2010-10-13	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA3039943C (en)	2008-02-28	2021-07-13	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as cftr modulators
SI2615085T1 (sl)	2008-03-31	2015-11-30	Vertex Pharmaceuticals Incorporated	Piridilni derivati kot cftr-modulatorji
WO2011008931A2 (en)	2009-07-15	2011-01-20	Cystic Fibrosis Foundation Therapeutics, Inc.	Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
AU2011230508B2 (en) *	2010-03-25	2016-04-28	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihyderoxypropyl)-6-fluoro-2- (1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide
TW201309706A (zh) *	2011-07-22	2013-03-01	Actelion Pharmaceuticals Ltd	作為ｐ２ｘ７受體拮抗劑之雜環醯胺衍生物
US9790219B2 (en)	2014-03-13	2017-10-17	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for increasing CFTR activity
AU2016333907A1 (en) *	2015-10-09	2018-04-12	AbbVie S.à.r.l.	Novel compounds for treatment of cystic fibrosis
CN108463223A (zh) *	2015-10-09	2018-08-28	艾伯维公司	用于治疗囊性纤维化的增效剂-校正剂组合

2015
- 2015-10-28 CN CN201580071713.XA patent/CN107405337B/zh active Active
- 2015-10-28 MY MYPI2017701450A patent/MY194313A/en unknown
- 2015-10-28 EP EP15854320.7A patent/EP3212189B1/en active Active
- 2015-10-28 UA UAA201705277A patent/UA122965C2/uk unknown
- 2015-10-28 ES ES15854320T patent/ES2830279T3/es active Active
- 2015-10-28 WO PCT/US2015/057837 patent/WO2016069757A1/en active Application Filing
- 2015-10-28 KR KR1020237008262A patent/KR20230040378A/ko not_active Application Discontinuation
- 2015-10-28 SI SI201531390T patent/SI3212189T1/sl unknown
- 2015-10-28 LT LTEP15854320.7T patent/LT3212189T/lt unknown
- 2015-10-28 AU AU2015339336A patent/AU2015339336B2/en active Active
- 2015-10-28 RU RU2017118552A patent/RU2718060C2/ru active
- 2015-10-28 JP JP2017542792A patent/JP6676646B2/ja active Active
- 2015-10-28 PE PE2017000764A patent/PE20171106A1/es unknown
- 2015-10-28 SG SG11201703391VA patent/SG11201703391VA/en unknown
- 2015-10-28 HU HUE15854320A patent/HUE052373T2/hu unknown
- 2015-10-28 MX MX2017005681A patent/MX366556B/es active IP Right Grant
- 2015-10-28 PL PL15854320T patent/PL3212189T3/pl unknown
- 2015-10-28 US US14/925,649 patent/US9642831B2/en active Active
- 2015-10-28 KR KR1020227037449A patent/KR102509720B1/ko active Application Filing
- 2015-10-28 CR CR20170227A patent/CR20170227A/es unknown
- 2015-10-28 CA CA3191010A patent/CA3191010A1/en active Pending
- 2015-10-28 CA CA2965981A patent/CA2965981C/en active Active
- 2015-10-28 DK DK15854320.7T patent/DK3212189T3/da active
- 2015-10-28 KR KR1020177014811A patent/KR102462038B1/ko active IP Right Grant
- 2015-10-28 SG SG10201803472QA patent/SG10201803472QA/en unknown
- 2015-10-28 RS RS20201328A patent/RS61267B1/sr unknown
- 2015-10-28 PT PT158543207T patent/PT3212189T/pt unknown
- 2015-10-30 UY UY0001036379A patent/UY36379A/es unknown
- 2015-10-30 TW TW104135934A patent/TWI691496B/zh active
- 2015-10-30 AR ARP150103536A patent/AR102492A1/es unknown
2017
- 2017-03-23 US US15/467,737 patent/US20170190693A1/en not_active Abandoned
- 2017-04-26 DO DO2017000104A patent/DOP2017000104A/es unknown
- 2017-04-27 PH PH12017500797A patent/PH12017500797A1/en unknown
- 2017-04-27 IL IL251996A patent/IL251996B/en active IP Right Grant
- 2017-04-28 MX MX2019008361A patent/MX2019008361A/es unknown
- 2017-04-28 CL CL2017001061A patent/CL2017001061A1/es unknown
- 2017-05-04 ZA ZA2017/03075A patent/ZA201703075B/en unknown
- 2017-05-30 CO CONC2017/0005421A patent/CO2017005421A2/es unknown
- 2017-05-31 EC ECIEPI201733565A patent/ECSP17033565A/es unknown
2018
- 2018-12-19 US US16/225,991 patent/US20190127356A1/en not_active Abandoned
2020
- 2020-10-15 HR HRP20201666TT patent/HRP20201666T1/hr unknown
- 2020-10-30 CY CY20201101027T patent/CY1123524T1/el unknown

Also Published As

Publication number	Publication date
CR20170227A (es)	2017-12-04
TWI691496B (zh)	2020-04-21
JP6676646B2 (ja)	2020-04-08
US20170190693A1 (en)	2017-07-06
KR20220151009A (ko)	2022-11-11
EP3212189A1 (en)	2017-09-06
US20190127356A1 (en)	2019-05-02
MY194313A (en)	2022-11-27
PH12017500797A1 (en)	2017-10-02
KR20230040378A (ko)	2023-03-22
DOP2017000104A (es)	2017-07-31
HRP20201666T1 (hr)	2020-12-25
PE20171106A1 (es)	2017-08-07
AR102492A1 (es)	2017-03-01
EP3212189B1 (en)	2020-09-09
MX366556B (es)	2019-07-12
UA122965C2 (uk)	2021-01-27
KR20170078796A (ko)	2017-07-07
MX2017005681A (es)	2018-01-12
HUE052373T2 (hu)	2021-04-28
CN107405337B (zh)	2021-02-09
CA2965981A1 (en)	2016-05-06
IL251996B (en)	2020-05-31
CN107405337A (zh)	2017-11-28
AU2015339336A1 (en)	2017-05-11
UY36379A (es)	2016-06-30
CL2017001061A1 (es)	2018-02-23
RU2017118552A (ru)	2018-12-04
TW201630904A (zh)	2016-09-01
SG10201803472QA (en)	2018-06-28
US9642831B2 (en)	2017-05-09
PT3212189T (pt)	2020-11-12
CO2017005421A2 (es)	2017-11-10
CA3191010A1 (en)	2016-05-06
KR102462038B1 (ko)	2022-11-02
MX2019008361A (es)	2019-09-09
WO2016069757A1 (en)	2016-05-06
ES2830279T3 (es)	2021-06-03
RU2718060C2 (ru)	2020-03-30
SG11201703391VA (en)	2017-05-30
LT3212189T (lt)	2020-11-25
KR102509720B1 (ko)	2023-03-15
DK3212189T3 (da)	2020-10-26
CY1123524T1 (el)	2022-03-24
CA2965981C (en)	2023-04-25
EP3212189A4 (en)	2018-05-09
RU2017118552A3 (sr)	2019-05-29
ECSP17033565A (es)	2019-02-28
PL3212189T3 (pl)	2021-03-08
JP2017533958A (ja)	2017-11-16
ZA201703075B (en)	2018-11-28
US20160120841A1 (en)	2016-05-05
SI3212189T1 (sl)	2020-11-30
BR112017008790A2 (pt)	2017-12-26
IL251996A0 (en)	2017-06-29
AU2015339336B2 (en)	2019-10-10

Publication	Publication Date	Title
ZA201703075B (en)	2018-11-28	Substituted chromanes and method of use
IL285433A (en)	2021-09-30	Converted tricycles and method of use
IL286316A (en)	2021-10-31	New micro-dystrophins and related method of use
ZA201802715B (en)	2019-09-25	Cannabis extracts and methods of preparing and using same
IL250415B (en)	2020-09-30	Antibodies against pd-l and methods of using them
IL255238A0 (en)	2017-12-31	Combinations of cannabinoids and acyl-ethanol-amines
GB201514756D0 (en)	2015-09-30	Compound and method of use
IL251988A0 (en)	2017-06-29	Compounds acting on glycans and methods of using them
GB201514760D0 (en)	2015-09-30	Compounds and method of use
HUE050761T2 (hu)	2021-01-28	Vegyületek és alkalmazási eljárások
IL249662A0 (en)	2017-02-28	Tampon and method for preparation
SG11201605915WA (en)	2016-08-30	Furo-3-carboxamide derivatives and methods of use
ZA201606450B (en)	2019-12-18	Compounds and their methods of use
GB201406245D0 (en)	2014-05-21	Vent value and method of use
GB201403697D0 (en)	2014-04-16	Compounds and methods of use
GB201416797D0 (en)	2014-11-05	Contianer and method of use thereof
GB201419990D0 (en)	2014-12-24	Hprseshoe and method of manufacture
GB201404133D0 (en)	2014-04-23	Garment and method of use thereof